BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Donnison T, von Delft A, Brown A, Swadling L, Hutchings C, Hanke T, Chinnakannan S, Barnes E. Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. Vaccine 2020;38:5036-48. [PMID: 32532545 DOI: 10.1016/j.vaccine.2020.05.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Kemming J, Thimme R, Neumann-Haefelin C. Adaptive Immune Response against Hepatitis C Virus. Int J Mol Sci 2020;21:E5644. [PMID: 32781731 DOI: 10.3390/ijms21165644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
2 Salimi Alizei E, Hofmann M, Thimme R, Neumann-Haefelin C. Mutational escape from cellular immunity in viral hepatitis: variations on a theme. Curr Opin Virol 2021;50:110-8. [PMID: 34454351 DOI: 10.1016/j.coviro.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Guest JD, Pierce BG. Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Viruses 2021;13:837. [PMID: 34063143 DOI: 10.3390/v13050837] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Hajikhezri Z, Roohvand F, Maleki M, Shahmahmoodi S, Amirzargar AA, Keshavarz A, Seyed N, Farahmand M, Samimi-Rad K. HCV Core/NS3 Protein Immunization with "N-Terminal Heat Shock gp96 Protein (rNT (gp96))" Induced Strong and Sustained Th1-Type Cytokines in Immunized Mice. Vaccines (Basel) 2021;9:215. [PMID: 33802466 DOI: 10.3390/vaccines9030215] [Reference Citation Analysis]
5 Provine NM, Amini A, Garner LC, Spencer AJ, Dold C, Hutchings C, Silva Reyes L, FitzPatrick MEB, Chinnakannan S, Oguti B, Raymond M, Ulaszewska M, Troise F, Sharpe H, Morgan SB, Hinks TSC, Lambe T, Capone S, Folgori A, Barnes E, Rollier CS, Pollard AJ, Klenerman P. MAIT cell activation augments adenovirus vector vaccine immunogenicity. Science 2021;371:521-6. [PMID: 33510029 DOI: 10.1126/science.aax8819] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
6 Sklar MJ, Maiolatesi S, Patterson N, Sedegah M, Limbach K, Teneza-Mora N, Chuang I, Hollis-Perry KM, Banania JG, Guzman I, Ganeshan H, Reyes S, Hollingdale MR, Wong M, Lindstrom A, Reyes A, Alcorta Y, Garver L, Bankard K, Belmonte A, Belmonte M, Huang J, Gowda K, Inoue S, Velasco R, Bergmann-Leitner E, Hutter J, Lee T, Adams N, Chaudhury S, Hunt D, Tamminga C, Berrie E, Bellamy D, Bittaye M, Ewer K, Diggs C, Soisson LA, Lawrie A, Hill A, Richie TL, Villasante E, Epstein JE, Duplessis CA. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults. PLoS One 2021;16:e0256980. [PMID: 34495988 DOI: 10.1371/journal.pone.0256980] [Reference Citation Analysis]
7 Phelps CC, Walker CM, Honegger JR. Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. Viruses 2021;13:1351. [PMID: 34372558 DOI: 10.3390/v13071351] [Reference Citation Analysis]